Nantahala Capital Management LLC Invests $2.91 Million in Artiva Biotherapeutics, Inc. $ARTV

Nantahala Capital Management LLC acquired a new position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 300,000 shares of the company’s stock, valued at approximately $2,910,000. Nantahala Capital Management LLC owned approximately 0.61% of Artiva Biotherapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. 5AM Venture Management LLC purchased a new stake in Artiva Biotherapeutics during the second quarter worth $22,827,049. ADAR1 Capital Management LLC acquired a new stake in Artiva Biotherapeutics during the second quarter valued at $1,151,000. Blue Owl Capital Holdings LP purchased a new position in Artiva Biotherapeutics in the second quarter valued at $8,483,000. BlackRock Inc. purchased a new position in Artiva Biotherapeutics in the second quarter valued at $6,739,000. Finally, State of Wyoming purchased a new position in Artiva Biotherapeutics in the second quarter valued at $45,000.

Artiva Biotherapeutics Price Performance

Shares of Artiva Biotherapeutics stock opened at $11.09 on Friday. The stock has a market capitalization of $542.19 million, a P/E ratio of -3.36 and a beta of 2.16. The business has a 50 day simple moving average of $10.38 and a two-hundred day simple moving average of $8.49. Artiva Biotherapeutics, Inc. has a 12 month low of $2.22 and a 12 month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.63). As a group, research analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.62 EPS for the current fiscal year.

Insider Activity

In other Artiva Biotherapeutics news, Director Ra Capital Management, L.P. bought 24,944 shares of Artiva Biotherapeutics stock in a transaction on Friday, July 31st. The shares were bought at an average price of $9.93 per share, for a total transaction of $247,693.92. Following the completion of the transaction, the director directly owned 17,329,570 shares of the company’s stock, valued at $172,082,630.10. This trade represents a 0.14% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. In the last three months, insiders have purchased 1,965,251 shares of company stock worth $16,188,035. 1.80% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ARTV shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. HC Wainwright boosted their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Wedbush upped their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a research note on Monday, May 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $41.00 target price on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.